Empowered Patient Podcast

Alain Moussy, Co-Founder and CEO, AB Science has applied their lead compound Masitinib to target mast cells and macrophage, also known when presenting with CNS as microglia, from the innate immune system to treat Lou Gehrig's disease, multiple sclerosis, Alzheimer's disease, tumors, and pancreatic cancer. Now AB Science is turning their attention to fighting the cytokine storm in COVID-19 patients by targeting and blocking mast cells and macrophages which are known to contribute to the inflammation.

#masitinib #PancreaticCancer #COVID19 #Alzheimers

AB-Science.com

Listen to the podcast here.

Alain Moussy, Co-Founder and CEO, AB Science has applied their lead compound Masitinib to target mast cells and macrophage, also known when presenting with CNS as microglia, from the innate immune system to treat Lou Gehrig's disease, multiple sclerosis, Alzheimer's disease, tumors, and pancreatic cancer. Now AB Science is turning their attention to fighting the cytokine storm in COVID-19 patients by targeting and blocking mast cells and macrophages which are known to contribute to the inflammation.

#masitinib #PancreaticCancer #COVID19 #Alzheimers

AB-Science.com

Download the transcript here

Dr. David Solomon, CEO, Pharnext is deploying their innovative drug discovery platform that uses genetic data, big data and AI to determine combinations that are novel and non-obvious to find treatments for rare diseases. With a focus on Charcot-Marie-Tooth, a rare neurologic peripheral neuropathy with no current treatments, Pharnext is seeing their drug PXT3003 stabilize patients with CMT1A, strengthen nerve transduction and also cause significant clinical improvement.

@pharnext #pharnext #drugdiscovery #CMT #PXT3003

Pharnext.com

Listen to the podcast here

Dr. David Solomon, CEO, Pharnext is deploying their innovative drug discovery platform that uses genetic data, big data and AI to determine combinations that are novel and non-obvious to find treatments for rare diseases. With a focus on Charcot-Marie-Tooth, a rare neurologic peripheral neuropathy with no current treatments, Pharnext is seeing their drug PXT3003 stabilize patients with CMT1A, strengthen nerve transduction and also cause significant clinical improvement.

@pharnext #pharnext #drugdiscovery #CMT #PXT3003

Pharnext.com

Download the transcript here

Sean Tucker, Founder and Chief Scientific Officer, Vaxart is on a mission to expand the choices for a COVID-19 vaccine by producing an effective oral vaccine in tablet form which would allow for more efficient distribution and ease of administering particularly to needle-adverse people. Building on experience developing an oral tablet for an influenza vaccine, Vaxart has created a technology to trick the immune system in the intestine to recognize the protein as something that needed to mount immune response and then develop memory so that it works as a vaccine.

#Vaxart #COVIDVaccine #COVIDTabletVaccine #COVIDORalVaccine #PillVaccineAgainstPandemic #warmCOVIDVaccine

Vaxart.com

Listen to the podcast here

Sean Tucker, Founder and Chief Scientific Officer, Vaxart is on a mission to expand the choices for a COVID-19 vaccine by producing an effective oral vaccine in tablet form which would allow for more efficient distribution and ease of administering particularly to needle-adverse people. Building on experience developing an oral tablet for an influenza vaccine, Vaxart has created a technology to trick the immune system in the intestine to recognize the protein as something that needed to mount immune response and then develop memory so that it works as a vaccine.

#Vaxart #COVIDVaccine #COVIDTabletVaccine #COVIDORalVaccine #PillVaccineAgainstPandemic #warmCOVIDVaccine

Vaxart.com

Download the transcript here

Luke Wilson VP Constella Intelligence talks about the digital risk protection space and the increasing attacks on healthcare networks in large part due to opportunities created for cyber criminals by COVID-19. With a lack of awareness about the need for good cyber hygiene and the explosion of new online activities, hospitals and other large healthcare institutions are seeing ransomware and nefarious online activities growing at an alarming rate. This interview was recorded right before 4iQ and ALTO joined to form Constella Intelligence.

@ConstellaIntel #COVID19 #cybercrime #digitalrisk #cyberhygiene

ConstellaIntelligence.com

Listen to the podcast here

Luke Wilson VP Constella Intelligence talks about the digital risk protection space and the increasing attacks on healthcare networks in large part due to opportunities created for cyber criminals by COVID-19. With a lack of awareness about the need for good cyber hygiene and the explosion of new online activities, hospitals and other large healthcare institutions are seeing ransomware and nefarious online activities growing at an alarming rate. This interview was recorded right before 4iQ and ALTO joined to form Constella Intelligence.

@ConstellaIntel #COVID19 #cybercrime #digitalrisk #digitalhygiene

ConstellaIntelligence.com

Download the transcript here

Dr. Jim Woody, CEO, 180 Life Sciences is one of four world-renowned scientists that have come together to form 180 LS to focus on treating inflammation, fibrosis and pain. Jim discusses the company's lead clinical program using anti-TNF to treat Dupuytren's contracture, a fibrotic disease of the hand. With a goal of preventing the fibrosis, Jim is drawing on his early invention of the first anti-TNF drug that worked in rheumatoid arthritis, Crohn's disease and psoriasis with an eye to preventing frozen shoulder as well.

#fibrosis #inflammation #Dupuytren #antiTNF

180LifeSciences.com

Listen to the podcast here

Dr. Jim Woody, CEO, 180 Life Sciences is one of four world-renowned scientists that have come together to form 180 LS to focus on treating inflammation, fibrosis and pain. Jim discusses the company's lead clinical program using anti-TNF to treat Dupuytren's contracture, a fibrotic disease of the hand. With a goal of preventing the fibrosis, Jim is drawing on his early invention of the first anti-TNF drug that worked in rheumatoid arthritis, Crohn's disease and psoriasis with an eye to preventing frozen shoulder as well.

#fibrosis #inflammation #Dupuytren #antiTNF

180LifeSciences.com

Download the transcript here